Orchestra BioMed Holdings, Inc. filings document the governance, financing and material agreements of a biomedical company developing AVIM Therapy and Virtue SAB through strategic medical-device partnerships. Current reports describe revenue participation rights, strategic financing, distribution and right-of-first-refusal arrangements, underwritten common stock and pre-funded warrant offerings, investor presentations, and other business updates.
Proxy materials cover board elections, auditor ratification, executive compensation votes, equity and employee stock purchase plans, and related annual-meeting governance. The filing record also includes compensatory-arrangement disclosures for executive bonus plans, registration-statement references, exhibit filings and capital-structure disclosure tied to its cardiovascular product candidates.
Orchestra BioMed Holdings, Inc. President and Chief Operating Officer Darren Sherman sold 15,000 shares of common stock on October 1, 2026, at a weighted average price of $6.36 per share. The sales were made under a Rule 10b5-1 trading plan adopted December 18, 2025; prices ranged from $6.20 to $6.48. Sherman directly held 1,119,402 shares after the sale. A separate 2,000-share holding was reported indirectly through his son, and Sherman disclaimed beneficial ownership of those securities.
Orchestra BioMed Holdings, Inc. (OBIO) reports that Darren Sherman proposes to sell 15,000 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $94,050.00 and an approximate sale date of October 1, 2026. The notice lists three sales during the preceding three months: 15,000 shares on July 1, 2026, for $64,066.02; 15,000 shares on August 3, 2026, for $61,291.68; and 15,000 shares on September 1, 2026, for $74,059.38. The shares proposed for sale are described as acquired through restricted stock vesting on November 25, 2024.
Orchestra BioMed Holdings, Inc. (OBIO) announced that 330 patients had been randomized in the BACKBEAT global pivotal trial as of September 30, 2026, exceeding its 316-patient enrollment target. The trial evaluates investigational AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension despite medication. Its FDA-approved protocol specifies 284 evaluable randomized subjects for primary-endpoint analysis, with the enrollment target accounting for potential loss to follow-up.
Patients are randomized between AVIM Therapy with continued medical therapy and pacing, and continued medical therapy with standard pacing alone. Orchestra BioMed and Medtronic intend to submit primary-endpoint results for consideration as a late-breaking presentation at a major cardiovascular conference in Q2 2027. Assuming positive trial results, Medtronic plans to submit marketing applications to the FDA and other global regulatory agencies.
Orchestra BioMed Holdings, Inc. (OBIO) reported that Chief Executive Officer and Chairperson David P. Hochman had 6,566 shares of Common Stock withheld on September 10, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units. According to the disclosure, no shares were sold in the market in connection with this event.
After these tax-withholding transactions, Hochman held 1,067,463 shares directly and 432,916 shares indirectly through the DPH 2008 Trust, as well as additional indirect holdings through several family trusts. No Rule 10b5-1 trading plan is reported for these transactions.
Orchestra BioMed Holdings, Inc. (OBIO) furnished an investor presentation outlining a capital‑efficient, partnership‑driven model focused on cardiovascular devices. The company highlights two pivotal‑stage programs: AVIM Therapy, a pacemaker‑delivered treatment for hypertension and hypertensive heart disease, and Virtue SAB, a sirolimus AngioInfusion balloon for coronary artery disease.
The presentation describes large target markets (multi‑billion‑dollar annual TAMs), Breakthrough Device Designations for AVIM Therapy indications, and IDE pivotal trials for both AVIM (BACKBEAT Trial) and Virtue SAB that are actively enrolling. OBIO reports receiving more than $185 million in strategic capital from partners including Medtronic, Terumo and Ligand, with current cash described as providing runway through 2027.
Orchestra BioMed Holdings, Inc. (OBIO) reported that Chief Executive Officer and Chairperson David P. Hochman purchased 10,000 shares of common stock on September 3, 2026 in an open-market or private transaction at a weighted average price of $4.79 per share, with individual prices ranging from $4.73 to $4.79. Following this purchase, he directly holds 1,070,746 common shares, in addition to several indirect holdings through family trusts.
Orchestra BioMed Holdings, Inc. (OBIO) insider Darren Sherman, President, Chief Operating Officer and director, reported a sale of 15,000 shares of Common Stock on September 1, 2026 at a weighted average price of $4.94 per share, in open-market or private transactions executed under a Rule 10b5-1 trading plan adopted on December 18, 2025. Following this sale, he directly holds 1,134,402 shares of Common Stock. A separate indirect holding of 2,000 shares is reported as held by his son, for which he disclaims beneficial ownership.
Orchestra BioMed Holdings, Inc. (OBIO) insider Darren Sherman has filed a Form 144 indicating an intent to sell up to 15,000 shares of common stock through Fidelity Brokerage Services LLC on or after September 1, 2026. The shares relate to restricted stock vesting on November 25, 2024 and are characterized as compensation.
Over the prior three months, Darren Sherman reported Rule 144 sales of 15,000 shares of OBIO common stock in each of June, July, and August 2026, with aggregate proceeds of $58,049.53, $64,066.02, and $61,291.68, respectively.
Orchestra BioMed Holdings, Inc. (OBIO) reported that Chief Financial Officer Andrew Taylor Lawrence had 3,076 shares of common stock withheld on 2026-08-26 to satisfy tax withholding obligations related to vesting of restricted stock units. The filing states that no shares were sold in the market. Following this tax-withholding transaction, Lawrence directly holds 589,989 shares of OBIO common stock.
For Orchestra BioMed Holdings, Inc. (OBIO), President and Chief Operating Officer Darren Sherman reported two transactions in Common Stock on August 26, 2026. First, 4,925 shares were withheld by the company at $5.26 per share to satisfy tax withholding obligations upon vesting of restricted stock units, leaving 1,149,402 shares held directly; no shares were sold in the market for this event. Second, an account held by Mr. Sherman’s son purchased 2,000 shares at $5.33 per share, reported as indirect ownership, but Mr. Sherman disclaims beneficial ownership of those shares.